VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced participation in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) announced participation in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022. CEO David Domzalski will present at 12:30 p.m. ET and management will host investor meetings on the same day. A webcast link is provided for those interested in attending, with a replay available for 90 days post-event. VYNE is focused on developing innovative therapies for immuno-inflammatory conditions, utilizing its proprietary BET domain platform, including lead programs VYN201 and VYN202.
Details
News Market Reaction – VYNE
The recorded move for VYNE in the trading session of this news was +3.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, and management will host investor meetings on December 1, 2022.
| Piper Sandler 34th Annual Healthcare Conference | |
| Date: | Thursday, December 1, 2022 |
| Time: | 12:30 p.m. ET |
| Format: | Company presentation |
| 1x1 Meetings: | Thursday, December 1, 2022 |
| Webcast Link: | https://event.webcasts.com/starthere.jsp?ei=1582698&tp_key=84bac10d55 |
| a replay will be available on the VYNE website for 90 days, following the presentation | |
Please contact your Piper Sandler representative if you would like to schedule a one-on-one meeting during the conference.
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.